Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) have earned an average rating of “Moderate Buy” from the seven analysts that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $13.33.
Several research firms recently issued reports on ARQT. Needham & Company LLC reiterated a “buy” rating and issued a $18.00 price target on shares of Arcutis Biotherapeutics in a report on Thursday, August 15th. Jefferies Financial Group started coverage on shares of Arcutis Biotherapeutics in a research report on Wednesday, August 28th. They set a “buy” rating and a $15.00 target price on the stock.
View Our Latest Stock Report on ARQT
Insider Activity at Arcutis Biotherapeutics
Institutional Investors Weigh In On Arcutis Biotherapeutics
Large investors have recently modified their holdings of the business. Creative Planning bought a new position in shares of Arcutis Biotherapeutics during the 3rd quarter valued at about $127,000. Wesbanco Bank Inc. bought a new position in Arcutis Biotherapeutics in the third quarter valued at approximately $955,000. Inspire Investing LLC acquired a new position in shares of Arcutis Biotherapeutics in the third quarter valued at approximately $412,000. Perceptive Advisors LLC increased its position in shares of Arcutis Biotherapeutics by 107.8% during the second quarter. Perceptive Advisors LLC now owns 1,558,500 shares of the company’s stock worth $14,494,000 after acquiring an additional 808,500 shares in the last quarter. Finally, Capital Impact Advisors LLC acquired a new stake in shares of Arcutis Biotherapeutics during the second quarter worth $606,000.
Arcutis Biotherapeutics Price Performance
ARQT opened at $8.41 on Tuesday. The company has a debt-to-equity ratio of 1.09, a current ratio of 8.46 and a quick ratio of 8.19. The stock has a market capitalization of $973.58 million, a P/E ratio of -2.87 and a beta of 1.17. The company’s 50 day simple moving average is $9.78 and its 200-day simple moving average is $9.43. Arcutis Biotherapeutics has a one year low of $1.76 and a one year high of $13.17.
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.06. The firm had revenue of $30.86 million for the quarter, compared to the consensus estimate of $31.00 million. Arcutis Biotherapeutics had a negative return on equity of 145.41% and a negative net margin of 150.51%. During the same quarter in the prior year, the business earned ($1.16) EPS. Sell-side analysts anticipate that Arcutis Biotherapeutics will post -1.56 earnings per share for the current fiscal year.
Arcutis Biotherapeutics Company Profile
Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.
Read More
- Five stocks we like better than Arcutis Biotherapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Learn Technical Analysis Skills to Master the Stock Market
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.